Annual Report 2025

Purpose, strategy and culture

Purpose

At Novo Nordisk, our purpose remains clear: driving change to defeat serious chronic diseases. Alongside our purpose, balancing our triple bottom line of financial, social and environmental responsibility remains fundamental to our identity.

Strategy

Our strategy focuses on leading in Obesity, Diabetes & related comorbidities, through patient centricity, innovation and affordable access. In Obesity, we will lead by addressing patients’ diverse needs and supporting them throughout their care journey. In Diabetes, we will strengthen leadership with a cardiorenal focus. In addition, we will continue to strengthen Rare Disease leadership in rare blood and rare endocrine disorders.

Significant unmet need persists with almost 1 billion people living with obesity and around 600 million living with diabetes. This represents a major opportunity and obligation to serve many more patients.

The updated strategy marks a shift from expansion into new, dedicated therapy areas as standalone (CVD, CKD, MASH) towards going deeper into our core areas, Obesity and Diabetes.

1. Chronic kidney disease.

2. Cardiovascular disease.

3. Metabolic dysfunction-associated steatohepatitis.

Novo Nordisk strategy graphic (graphic)

Culture

The Novo Nordisk Way Essentials

  1. We create value by having a patient-centred business approach.
  2. We set ambitious goals and are empowered to achieve them.
  3. We are accountable for our financial, environmental and social performance.
  4. We are curious and innovate for the benefit of patients and society at large.
  5. We build and maintain good relations with our stakeholders.
  6. We value diversity and treat everyone with respect.
  7. We focus on performance and personal development.
  8. We have a healthy and engaging working environment.
  9. We strive for agility and simplicity in everything we do.
  10. We never compromise on quality and ethics.